Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b ZS-9 to reduce pre-dialysis hyperkalemia in hemodialysis patients
jRCT2080223796Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in hyperkalemia and end-stage kidney disease (ESKD) comparing Sodium zirconium cyclosilicate arm with Placebo arm (2 arms). Started Feb 2018; status: completed.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080223796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223796.